Intravesical Therapy of Superficial Urothelial Bladder Cancer with BCG and Epirubicin 50 Mg - Comparative Analysis
, , , , et
13 juil. 2022
À propos de cet article
Publié en ligne: 13 juil. 2022
Pages: 70 - 73
Reçu: 18 janv. 2022
Accepté: 11 mai 2022
DOI: https://doi.org/10.2478/jbcr-2022-0009
Mots clés
© 2022 Nikolay I. Nikolov et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Bladder cancer is a heterogeneous disease in molecular, histological and clinical aspects. Treatment should also be considered from different angles - surgery, intravesical chemo- or immunotherapy, radiation therapy and lifestyle changes. Intravesical treatment of superficial bladder cancer with Еpirubicin or Bacillus Calmette-Guérin (BCG) is a continuation of surgical treatment to reduce or eliminate further recurrence.